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Lack of BRAF Mutations in Spitz Nevi
To the Editor:
Spitz nevi are benign melanocytic neoplasms that usually
occur in childhood and adolescence. Although the diag-
nosis of classical Spitz nevus can be reliably achieved by
conventional histopathologic criteria, there is a subset of
cases in which it is difficult or impossible to differentiate
Spitz nevi from melanoma with Spitz-like features (Barnhill
et al, 1999). There are many cases described in the literature
of Spitz nevi misdiagnosed as melanoma or vice versa.
There is good documentation of histologically atypical Spitz
nevi or lesions originally misdiagnosed as Spitz nevi,
metastasizing to regional lymph nodes and leading to
widespread metastasis and fatal outcome (Ghorbani et al,
1996; Barnhill et al, 1999; Lohmann et al, 2002).
BRAF belongs to RAF family of proteins (RAF1, ARAF,
BRAF) that encode serine-threonine kinases and act in the
RAS/RAF/MAPK pathway to transduce regulatory signals from
Ras to MEK1/2 (Peyssonnaux and Eychene, 2001). Recently,
mutations in BRAF have been identified in 59–80% of
melanoma samples (Brose et al, 2002; Davies et al, 2002;
Dong et al, 2003). More than 90% of BRAF mutations in
melanoma involve codon 599 in exon 15, V599E amino acid
substitution being the most common (Brose et al, 2002). Soon
after the identification of BRAF mutations in melanoma,
common melanocytic nevi were also shown to harbor
sequence alterations in BRAF, suggesting that deregulation of
the RAS/RAF/MAPK pathway is an early event in melanocytic
neoplasia. A high frequency of V599 codon substitution (73–
82%) has been reported in a variety of common melanocytic
nevi including compound, junctional, intradermal, congenital,
and dyplastic nevi (Pollock et al, 2003; Uribe et al, 2003). To
investigate whether Spitz nevi, like other melanocytic nevi,
have sequence alterations in BRAF, we analyzed Spitz nevi and
melanoma samples for mutations in exon 15 of BRAF.
This study has been approved by Western Institutional
Review Board (WIRB). Formalin-fixed, paraffin-embedded
30 Spitz nevi and 23 melanoma specimens were retrieved
from the archives of Dermatopathology Laboratory at
Columbia University. Histologic evaluation was performed
by a dermatopathologist (D.N.S.), and two groups of tumor
specimens were selected for this study: (1) ‘‘typical’’,
unequivocal Spitz nevi and (2) vertical growth phase
melanoma (invasive melanoma). The diagnostic criteria for
these tumors have been described previously (Paniago-
Pereira et al, 1978).
Paraffin-embedded specimens were cut in 5 mm thick-
ness and stained with hematoxylin. Tumor cells were micro-
dissected using a PixCell II Laser Capture Microdissection
System (Arcturus, Mountain View, California). Exon 15 of
BRAF was amplified by PCR using forward and reverse
primer sequences as described previously (Davies et al,
2002), and directly sequenced with an ABI 310 Sequencer
System (Applied Biosystems, Foster City, California). Muta-
tion confirmation was performed by sequencing with the
reverse strand primer, as well as PCR amplification and
sequencing with a different primer set.
A total of 53 specimens, 30 Spitz nevi and 23 melanoma
tumor samples, were analyzed in this study. The age of
patients with Spitz nevi ranged from two to 35 (average of
16 y), there were 14 female and 16 males in the group, and
all were histologically categorized as ‘‘typical’’ Spitz nevi
without unusual features. The melanoma cases selected
were all invasive melanomas, with an average Breslow
tumor thickness of 3.0 mm.
Mutations in BRAF exon 15 were detected in 13 of 23
(57%) of melanoma samples; however, sequence altera-
tions were not noted in 30 Spitz nevi (Table I). The most
frequent mutation was the T1796A substitution, resulting
in the V599E amino acid change in BRAF exon 15. This
mutation was detected in eight of 23 (35%) melanoma
specimens. In one sample, both V599E and T598I (C1793T)
mutations were observed (Fig 1A). Tandem bp substitutions,
GT1795-96AG and GT1795-96AA, which encode V599R
and V599K amino acid changes, respectively, were detected
in five melanoma tissues (Fig 1B, C).
BRAF mutation analyses reported to date have mostly
been on cell lines rather than primary melanoma samples.
Recently, V599 alterations have been reported in 14 of 25
(56%) primary melanoma tissues in one study (Uribe et al,
2003), and 28 of 97 (29%) melanoma specimens in another
study (Yazdi et al, 2003). We found mutation rate of BRAF
(exon 15) to be 57% in 23 primary melanomas. The most
common mutation in our series was V599E, accounting
for eight of 13 (62%) mutations detected. All of the 13
mutations identified affected the activation domain of BRAF
and led to V599 amino acid substitution. Our results are
consistent with the previous studies that activating BRAF
mutations are common in melanoma.
Common melanocytic nevi have also been shown to
harbor a high frequency of sequence alterations in BRAF.
In one study, 63 of 77 (82%) melanocytic nevi (including
congenital, intradermal, compound, dysplastic nevi) were
found to have V599E mutation (Pollock et al, 2003).
Similarly, V599 codon substitution has been reported in 16
of 22 (73%) of melanocytic nevi consisting of compound,
junctional and intradermal nevi (Uribe et al, 2003). These
data implicate the involvement of BRAF in the early phases
of melanocytic neoplasia. Spitz nevi are benign melanocytic
proliferations that are clinically and histologically distinct
from other benign melanocytic nevi. In an attempt to
investigate the role of BRAF in the development of Spitz
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nevi, we examined 30 Spitz nevi for mutations in BRAF exon
15. Interestingly, we did not find any sequence alterations.
During the preparation of our manuscript, Yazdi et al also
reported the absence of V599E mutation in 69 Spitz nevi
(Yazdi et al, 2003). The lack of common exon 15 BRAF
mutation in Spitz nevi further differentiates this tumor from
other common melanocytic nevi and suggests the involve-
ment of different gene/s in its development.
Spitz nevi are benign melanocytic proliferations that can
resemble melanoma on histologic examination. There is a
subset of cases in which it is difficult or impossible to
distinguish from melanoma. Over the years researchers
attempted to develop ancillary diagnostic techniques with
which one can differentiate Spitz nevus from melanoma. For
example, a significant difference in the frequencies and types
of chromosomal aberrations between melanomas and Spitz
nevi exist, and can be useful in differentiating these tumors in
some cases (Bastian et al, 1999; Bastian et al, 2003). But
techniques that are able to unequivocally discriminate
among borderline cases, and a large series confirming their
usefulness are lacking (Su et al, 2003). The lack of exon 15
BRAF mutation in Spitz nevi may be useful in distinguishing
these tumors from melanoma with Spitz-like features. The
mutational profile of BRAF in melanoma with Spitz-like
features, however, is unknown. Evaluation of a series of this
subset of melanoma will help to address this issue and
determine if BRAF mutations can help to distinguish Spitz
nevi from melanoma with Spitz-like features.
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Table I. Mutation frequencies of Spitz nevi and melanoma in
BRAF exon 15
Tumor type
Mutation frequency
in BRAF Exon 15
Mutation data
(number of cases)
Spitz nevus 0/30 (0%)
Melanoma 13/23 (57%) V599E (8)
V599K (4)
V599R (1)
T598I (1)
T A G  C T A C A  G   A A  A T C T
[G/A][T/G]
T A G C T A C A G A A  A T C T
[G/A][T/A]
T AG C T A AG    G  A A  A T CT
[C/T] [T/A]
ACA      ATA (T598I)
GTG GAG (V599E)
GTG AGG (V599 R)
GTG AAG (V599K)
A
B
C
Figure 1
BRAF exon 15 mutations in melanoma. (A) Two point mutations,
C1793T and T1796A substitution resulting in T598I and V599E amino
acid change, respectively. (B) GT1795-96GG, encoding the V599R amino
acid change. (C) GT1795-96AG, encoding the V599Kmissense mutation.
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